ABIVAX is a French biotech with a novel ulcerative colitis treatment in phase 3 trials. Click here to find out why I am ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Odds for desensitization and remission fell as patients missed consecutive doses of peanut oral immunotherapy, according to a ...

This article covers topics such as side effects, dosage, and how Simponi works. Simponi is a biologic and belongs to a drug class called tumor necrosis factor (TNF) blockers. The medication is not ...

Participants in the novel EAFToS study had high adherence rates to initiation and maintenance doses of ofatumumab in the ...

Other significant developments include promising phase 3 trial results for alopecia areata and the FDA's approval of Omvoh, which, along with solid earnings, position the company favorably even as ...

That's because they are administered in large doses, containing polymers which help create medication depots under the skin; those polymers can make up anything from 23% - 98% of the injectable ...

Dosage for Humira (adalimumab) may vary based on the condition it’s being used to treat. Also, your doctor may adjust your dosage over the course of your treatment. Be sure to take the Humira ...

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...

This article delves into the three approved assets in this class – AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Omvoh (mirikizumab), and J&J’s Tremfya (guselkumab) – and explores how ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...